gms | German Medical Science

GMDS 2013: 58. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e. V. (GMDS)

Deutsche Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie

01. - 05.09.2013, Lübeck

Benefit assessment of medical interventions: an international perspective

Meeting Abstract

Search Medline for

  • Jos Kleijnen - KSR Ltd., York, GB

GMDS 2013. 58. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e.V. (GMDS). Lübeck, 01.-05.09.2013. Düsseldorf: German Medical Science GMS Publishing House; 2013. DocAbstr.364

doi: 10.3205/13gmds304, urn:nbn:de:0183-13gmds3049

Published: August 27, 2013

© 2013 Kleijnen.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

This presentation will aim to give an overview about benefit assessment for reimbursement decision making from an international perspective. Examples will be used to highlight differences between countries in their legal frameworks, addressing methodological issues, uncertainty, quantification of extent of added benefit, and criteria for decision making. Focus will be on Germany, England/Wales, and the Netherlands, but also international guidance such as from the International Society for Pharmacoeconomics and Outcomes research (ISPOR), the European Network for Health Technology Assessment (EUnetHTA) and the Cochrane Collaboration will be considered. Current topics which are being intensively discussed include what to do when there is very little evidence, value based pricing, and how to make decisions about interventions for rare diseases (orphan drugs), these will also be addressed.